[Skip to Content]
[Skip to Content Landing]
Comment & Response
April 25, 2019

Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B

Author Affiliations
  • 1Clinical Epidemiology and EBM Unit, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, Mainland China
  • 2Genomics Research Center, Academia Sinica, Taipei, Taiwan
JAMA Oncol. 2019;5(6):915-916. doi:10.1001/jamaoncol.2019.0647

To the Editor We read with great interest the article entitled “Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.”1 The authors concluded that tenofovir treatment was associated with a significantly lower risk of hepatocellular carcinoma (HCC) than entecavir treatment in treatment-naive patients with chronic hepatitis B. This study may potentially affect clinical practice, although Flemming and Terrault2 have stated in their accompanying editorial that this study should not lead to a widespread paradigm shift in selecting tenofovir treatment over entecavir treatment.